Study: Tesmilifene/Doxorubicin Combination Therapy Results Promising

Women with breast cancer receiving Tesmilifene/Doxorubicin combination therapy may survive 50 percent longer than those receiving Doxorubicin alone, according to a study released by the National Cancer Institute of Canada (NCIC).

The patients receiving the Tesmilifene/Doxorubicin therapy lived 23.6 months compared with 15.6 months with Doxorubicin alone, according to the study presented at the American Society of Clinical Oncologists.

The study, stopped in 1999, was a Phase III trial conducted by the NCIC prior to acquisition of the commercial rights to the Tesmilifene by YM BioScience (YMB). The NCIC has continued to follow the participants in that study.

Tesmilifene has been primarily tested as a drug therapy for prostate cancer. "In view of these recent developments, we intend to do a thorough analysis of the data and in conjunction with opinion leaders in the field of breast cancer to decide on the optimal development path for Tesmilifene. At the same time, we continue to be committed to the prostate indication for this product," said David Allan, Chairman and CEO of YMB.

Other Sources: YM BioSciences, Inc.